The Cholesterol-ASCVD Connection:
Is Your Patient at Risk?

Many patients with, or at high risk for, atherosclerotic cardiovascular disease (ASCVD) do not achieve guideline-recommended LDL-C targets despite currently available lipid-lowering therapies. The HEART-3 Study is evaluating whether a single administration of the gene-editing investigational medicine, VERVE-102, can durably lower LDL-C through targeted inactivation of the hepatic PCSK9 gene. VERVE-102 is being investigated as a potential treatment approach for patients with, or at risk for, ASCVD whose LDL-C remains elevated despite stable lipid-lowering therapy.

Do you know any patients who meet the following criteria?

Criterias:
  • Are 18 to 70 years of age
  • Have established atherosclerotic cardiovascular disease (ASCVD) and/or are at high risk of ASCVD
  • Are on appropriate background lipid-lowering therapy and require additional LDL-C lowering
  • Evidence of a potentially unstable or acute cardiovascular disorder, such as:
  • Planned coronary, cerebrovascular, or peripheral revascularization
  • Current exertional angina
  • Current New York Heart Association Class III or IV heart failure symptoms
  • Recent acute myocardial infarction (MI), unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or ischemic stroke/transient ischemic attack (TIA)
  • Current or recent significant cardiac arrhythmia or rhythm disorder
  • History of hemorrhagic stroke
  • History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)
  • Chronic liver disease
  • Current treatment with a PCSK9 inhibitor, or prior treatment within a specified timeframe
  • Type 1 diabetes or inadequately controlled type 2 diabetes
Additional criteria may apply.

Participants will receive all study-related treatment and study-related care at no cost, and may be reimbursed for travel and expenses.

About the
HEART-3 Study

HEART-3 is a Phase 2, randomized, double-blind, placebo-controlled study evaluating VERVE-102, an investigational gene-editing medicine designed to durably lower low-density lipoprotein cholesterol (LDL-C) by turning off the PCSK9 gene in liver cells. The study is enrolling adult participants with, or at high risk for, atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains elevated despite stable lipid-lowering therapy.
The investigational medicine, VERVE-102, has not been approved by the FDA or any other regulatory authority for any use.

Primary Objective

To evaluate whether the investigational medicine, VERVE-102, is superior to placebo in lowering LDL-C

Primary Endpoint

Percent change in LDL-C from baseline
Participants who meet entry criteria will be randomized to receive one of the following:

Dose 1

of the investigational medicine, VERVE-102

Dose 2

of the investigational medicine, VERVE-102

Dose 3

of the investigational medicine, VERVE-102

Placebo

The investigational medicine, VERVE-102, and the placebo are both administered as a one-time IV infusion. Participants initially randomized to receive the placebo may be eligible to continue in a later part of the study.
Each participant will be monitored for at least 1 year after receiving VERVE-102. Participants who receive VERVE-102 will be asked to join a separate long-term follow-up study, which provides safety monitoring for a total of 15 years after their dose.

About the
HEART-3 Study

HEART-3 is a Phase 2, randomized, double-blind, placebo-controlled study evaluating VERVE-102 (LY4636581), a one-time investigational treatment designed to durably lower low-density lipoprotein cholesterol (LDL-C) by inactivating the PCSK9 gene in the liver, for adult participants who have, or at high risk for, ASCVD and an elevated LDL-C despite stable treatment.
VERVE-102 is investigational and has not been approved by the FDA or any other regulatory authority for any use.

Primary Objective

To evaluate if VERVE-102 is superior to placebo in lowering LDL-C

Primary Endpoint

Percent change in LDL-C from baseline to Day 90
Participants who meet entry criteria will be randomized in a 2:2:2:1 ratio to receive one of the following:
  • Dose 1 of VERVE-102
  • Dose 2 of VERVE-102
  • Dose 3 of VERVE-102
  • Placebo
VERVE-102 and the placebo are both administered as a one-time IV infusion. Participants initially randomized to receive the placebo may become eligible to receive VERVE-102 in a later part of the study.

Refer a Patient
for the HEART-3 Study

Complete the form below to refer a potential candidate to the HEART-3 Study team. A member of the study team will follow up with you and/or your patient.

[Referral Form]

Created by CTM
© 2026 Clinical Trial Media. All Rights Reserved. The images depicted contain models and are being used for illustrative purposes only.
Created by CTM
© 2026 Clinical Trial Media. All Rights Reserved. The images depicted contain models and are being used for illustrative purposes only.
Privacy Policy Legal Notice Consumer Health Privacy Notice Cookie Notice
Your Privacy Choice